ALRX, ACCP, NVSR, LVLV, BBYB, OOGI, LJPC, PMDP, LLBO, BZCN, DSCO Daily Market Movers Digest Midday Report for Friday, July 24th from OTCPicks.com

ALRX, ACCP, NVSR, LVLV, BBYB, OOGI, LJPC, PMDP, LLBO, BZCN, DSCO Daily Market Movers Digest Midday Report for Friday, July 24^th from OTCPicks.com

 

Our Stocks to Watch today include AlphaRx Inc. (OTCBB: ALRX), Access Pharmaceuticals Inc. (OTCBB: ACCP), NavStar Technologies Inc. (OTC: NVSR), LEVEL Vision Electronics Ltd. (OTC: LVLV), Baby Bee Bright Corp. (OTC: BBYB), Odyssey Oil & Energy Inc. (OTCBB: OOGI), La Jolla Pharmaceutical Co. (Nasdaq: LJPC), Plateau Mineral Development Inc. (OTC: PMDP), Lifeline BioTechnologies Inc. (OTC: LLBO), BizAuctions Inc. (OTC: BZCN) and Discovery Laboratories Inc. (Nasdaq: DSCO).

 

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.

 

ALPHARX INCORPORATED (OTCBB: ALRX)

"Up 3.57% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/ALRX.php 

 

Company Profile: http://www.otcpicks.com/alpharx/alpharx.htm

 

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

 

ALRX News:

 

July 23 - AlphaRx Presents Positive Preclinical Data on Zysolin™ Inhalable Nanoparticles at Controlled Release Society Annual Meeting

 

AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results which demonstrated that an inhaled tobramycin nanoparticle (Zysolin) formulation was a more effective treatment in animal models of acute Pseudomonas aeruginosa pneumonia when compared to inhaled and injected conventional tobramycin solutions. The data was presented recently in an oral podium session at the 36th Annual Meeting and Exposition of the Controlled Release Society in Copenhagen, Denmark.

 

"These are very encouraging results, as they suggest that Zysolin employed in this route of administration may be more effective, providing significant advantages over conventional drug formulations," stated Joseph Schwarz, Ph.D., Chief Scientist of AlphaRx. "We believe that building on this data, additional research will lead us toward the development of a drug that targets and eradicates intracellular pathogens, which to date, have proven to be very difficult to treat clinically."

 

The study results demonstrate that Zysolin is significantly efficacious in acute pneumonia animal models induced by gram negative pathogens including P. aeruginosa. In these lethality-based studies, Zysolin consistently increased survival rate to 50% over a Tobramycin treatment group, wherein all untreated animals died within 24 hours after infection. P. aeruginosa is one of the most common and lethal pathogens responsible for ventilator-associated pneumonia in intubated patients, being directly responsible for death rates approaching 40%. This data suggests that the nanoparticulate formulation of Zysolin may utilize a unique mechanism of action differentiating it from conventional formulations, enhancing antimicrobial activity against gram negative pathogens. Zysolin has the potential to be a first-in-class anti-infective nanomedicine.

 

The Controlled Release Society (CRS) is an international organization consisting of 3,000 members from more than fifty countries. Two-thirds of CRS membership are from the pharmaceutical industry and one-third consist of academic and government members. The CRS is the premier multidisciplinary society dedicated to the promotion of the science, technology, and innovative delivery of bio-actives for the benefit of the society.

 

ABOUT ZYSOLIN™

 

Zysolin is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin improves the intracellular activity of Tobramycin — in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin, Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin.

 

ACCESS PHARMACEUTICALS INCORPORATED (OTCBB: ACCP)

"Up 23.81% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/ACCP.php 

 

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.

 

ACCP News:

 

July 23 - MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

 

Prevention of Oral Mucositis Expands Market Potential to Multiple Billions Of Dollars

 

Access Pharmaceuticals, Inc. (OTCBB: ACCP), announced that its European partner, SpePharm, is collecting data from a post approval study of MuGard in head and neck cancer patients undergoing radiation treatment in the UK showing prevention of oral mucositis. In a multi-center study expected to enroll a total of 280 patients, patients are provided with seven weeks of MuGard therapy, and begin using MuGard one week prior to radiation treatment and then throughout the subsequent six weeks of planned therapy. The first 140 patients being treated in this assessment study have been enrolled and treated, and as of the time of the update, none of these patients have experienced any oral mucositis.

 

"The initial feedback from SpePharm on their experience in the UK, with the first 140 patients in the assessment study, exceeds our most positive expectations," stated Jeffrey B. Davis, Access' President & CEO. "Normally, roughly 100% of patients undergoing radiation treatment for head and neck cancer experience some level of oral mucositis. This condition varies from a low level of discomfort and pain, up to Grades 3 and 4 which are debilitating to the point of patients discontinuing therapy. To see a result where all or substantially all of the patients using MuGard, and using it prophylactically, are not getting oral mucositis is extremely important with respect to treatment regimens. We believe the final data set will show that MuGard should be used prophylactically with all radiation or chemotherapy regimens that have the potential to lead to oral mucositis, greatly expanding the target market."

 

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, used prophylactically for patients undergoing chemotherapy and radiation therapy, is estimated to be in excess of $5 billion world-wide.

 

MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

 

NAVSTAR TECHNOLOGIES INCORPORATED (OTC: NVSR)

 

Detailed Quote: http://www.otcpicks.com/quotes/NVSR.php

 

Company Profile: http://www.otcpicks.com/navstar-technologies/navstar-technologies.htm

 

NavStar is focused on the creation of GPS products and services that provide wireless tracking of vehicles, equipment, and other valuable and personal assets. The goal is to be a total solutions provider.

 

NVSR News:

 

July 22 - Vehicle/Asset Tracking Forecast to Grow From $3.0B to $5.0B by 2011

 

NavStar Technologies, Inc. (OTC: NVSR), a multinational firm focused on developing and commercializing asset tracking and monitoring devices for vehicles and high value cargo with specific geographic focus in Latin America, has made available to shareholders and investors an independent research report on Vehicle/Asset tracking and monitoring.

 

According to the report, adoption of vehicle/asset tracking and monitoring is likely to be driven by factors such as:

 

* Increased recognition of tracking/monitoring benefits

* Worker productivity

* Administrative efficiency

* Reliable and affordable data communications

* Increase availability of wireless coverage

 

The report says that today only 10% of the 20M fleet vehicles in the US have Vehicle/Asset tracking devices and of the 12M fleet vehicles in Brazil and Mexico only 5% have Vehicle/Asset tracking devices.

 

N. Douglas Pritt, Chairman and CEO, confirmed that NavStar's business model for sales into Mexico, Latin and South America contemplates a very un-ambitious penetration of one-half of one percent of fleet vehicles.

 

NavStar also re-affirmed guidance regarding its expected financial performance over the next 5 years. The successful achievement of these financial objectives assumes the company's procurement of up to $2.0 million of funding in the 3rd quarter of this year and the completion of the services/software company.

 

N. Douglas Pritt, Chairman and CEO, said, "We continue to stay focused on getting POs from our distribution partners in Ecuador and Mexico. The Joint Venture for device and service sales into Japan is moving forward and next week we will announce agreements with distribution partners in Canada and the US that could have a significant impact on the financials as stated above."

 

For the complete research report, go to www.navstarinc.com and click the "What's New" link.

 

LEVEL VISION ELECTRONICS LTD. (OTC: LVLV)

 

Detailed Quote: http://www.otcpicks.com/quotes/LVLV.php

 

Company Profile: http://www.otcpicks.com/level-vision-electronics/level-vision-electronics.htm

 

LEVEL Vision Electronics is an ODM/OEM (designer and manufacturer) of consumer electronics (mainly Wireless Handsets) primarily concentrating on the world's emerging markets. Through its Unique Business Model, LEVEL works hand-in-hand with the Telcos to customize the products to their specific targeted market requirements. Our current 3D products can be found online at www.levelelectronics.com and our upcoming related wireless handset software products are currently under development.

 

LVLV News:

 

July 21 - LEVEL Upgrading Its Website With Investor Aimed Information

 

LEVEL Vision Electronics Ltd. (OTC: LVLV) announced that it is currently putting final touches on its newly re-designed Website to keep Investors and the public informed of current Information, weekly News and New Product updates.

 

The new design is in line with LEVEL's plans to reach out to the public and inform shareholders and prospective investors on the company's roadmap. The following is a brief description of what will be available on the website; Stock quotes, Management & Board of Directors' resumes, current Product line, General and Specific Information about the company and much more. The official website address, as well as its "Go Live" date, will be released in an upcoming press release.

 

"With heavy requests for more information about the company coming in via our current website, we felt it timely to design a new and updated site which will allow the public to view and read all current information and public news. The Company information will now be available in one convenient place with a fresh new look," said Habib Coriaty, President and CEO of Level Vision Electronics Ltd. "In addition to the recent announcement of our new Corporate Finance Advisors, Hilbroy Advisory Inc., we are reaching out to the world's markets with information aimed at current shareholders and prospective investors," added Mr. Jean-Francois Lefebvre, Vice President of LEVEL Vision Electronics Ltd.

 

BABY BEE BRIGHT CORPORATION (OTC: BBYB)

 

Detailed Quote: http://www.otcpicks.com/quotes/BBYB.php 

 

Company Profile: http://www.otcpicks.com/baby-bee-bright/baby-bee-bright.htm

 

Baby Bee Bright Corporation manages the Baby Bee BrightTM brand. Its executive staff, composed of professionals with over 30 years of experience in engineering research and marketing, have developed an innovative prenatal communication system, servicing the rapidly expanding expectant mother/prenatal market. The company has a patented, audio directional technology for its communicator which is designed for expectant mothers to safely and efficiently transmit music and sound to their babies. It allows mothers and family to bond with their babies before birth. Lullabies and classical music provide the baby with soothing sounds before and after birth.

 

BBYB News:

 

July 20 - Baby Bee Bright Targets UK Distribution Centers

 

Baby Bee Bright Corporation (OTC: BBYB), developer of a unique prenatal communication system, is expecting a marked increase in sales in the United Kingdom as a result of the release of the publication, “You and Your Family.” Considering the fact that the shipping cost from the US to the UK would increase the price of the Baby Bee Bright, it makes good sense to store inventory and ship it from a distribution center that is located in the UK. This would make all Baby Bee Bright products more affordable for the expectant mothers as well as speed up delivery time on both the retail and wholesale levels.

 

Fred Dahlman, CEO, stated, “Baby Bee Bright is ready to find distribution centers in the UK as well as possible retail outlets. When 'You and Your Family' is in the hands of 500,000 or more expectant mothers in 2010, we need to be ready for sales.”

 

ODYSSEY OIL & ENERGY INCORPORATED (OTCBB: OOGI)

"Up 10.53% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/OOGI.php

 

Odyssey Oil & Energy Inc. is a green technology company with two separate operating entities: carbon sequestration and advanced battery technology. These initiatives take the form of two operating entities called ALG Bio Oil Ltd and H-Power (PTY) Ltd.

 

OOGI News:

 

July 8 - H-Power Enters Into Negotiations With An International Wind Energy Company

 

Odyssey Oil & Energy, Inc. (OTCBB: OOGI) announces H-Power International (Pty) Ltd, 51% owned by Odyssey, has entered into negotiations with a major international wind energy company to utilize H-Power's patented Hybrid Battery Technology to store the power generated by the wind farms.

 

Once the power has been stored using the patented technology it can be used at anytime for distribution into an electricity grid. This revolutionary technology allows for the storage of alternative green energy including solar and wind power. Power storage has been a major obstacle for solar and wind energy producers for some time.

 

LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ: LJPC)

"Up 59.37% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/LJPC.php

 

La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed potential small molecule drug candidates to treat various other autoimmune and inflammatory conditions.

 

LJPC News:

 

July 23 - La Jolla Pharmaceutical Company Files Form 8-K with SEC

 

La Jolla Pharmaceutical Company (Nasdaq: LJPC) recently filed Form 8-K with the SEC, partially reading as follows:

 

Item 8.01 Other Events — Dismissal of BioMarin Lawsuit

 

On July 17, 2009, La Jolla Pharmaceutical Company (the "Company"), BioMarin Pharmaceutical Company ("BioMarin") and the Company's directors executed and delivered a Settlement Agreement and Mutual Release (the "Release"), pursuant to which (i) BioMarin released all claims previously asserted against the Company and its directors, as described in the Company's Current Report on Form 8-K filed June 12, 2009 (the "Form 8-K"), and (ii) the Company and its directors released all counterclaims that they may have otherwise asserted against BioMarin. Pursuant to the Release, BioMarin is required to dismiss the Lawsuit (defined below) with prejudice.

 

Other than the mutual release of claims and the dismissal of the Lawsuit, no other consideration is provided for in the Release and no amounts will be paid to BioMarin. BioMarin had sued the Company and its directors in California Superior Court (the "Lawsuit"), alleging breach of contract, breach of covenant of good faith and fair dealing, and breach of fiduciary duty relating to the Company's registration of stock sold to BioMarin in January 2009 in connection with a license and development agreement for Riquent. On July 17, 2009, La Jolla Pharmaceutical Company (the "Company"), BioMarin Pharmaceutical Company ("BioMarin") and the Company's directors executed and delivered a Settlement Agreement and Mutual Release (the "Release"), pursuant to which (i) BioMarin released all claims previously asserted against the Company and its directors, as described in the Company's Current Report on Form 8-K filed June 12, 2009 (the "Form 8-K"), and (ii) the Company and its directors released all counterclaims that they may have otherwise asserted against BioMarin.

 

Pursuant to the Release, BioMarin is required to dismiss the Lawsuit (defined below) with prejudice. Other than the mutual release of claims and the dismissal of the Lawsuit, no other consideration is provided for in the Release and no amounts will be paid to BioMarin. BioMarin had sued the Company and its directors in California Superior Court (the "Lawsuit"), alleging breach of contract, breach of covenant of good faith and fair dealing, and breach of fiduciary duty relating to the Company's registration of stock sold to BioMarin in January 2009 in connection with a license and development agreement for Riquent.

 

PLATEAU MINERAL DEVELOPMENT INCORPORATED (OTC: PMDP)

"Up 37.50% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/PMDP.php 

 

Plateau Mineral Development, Inc. specializes in the exploration and development of energy sources. Its partner, Plateau Mineral Development LLC, has been in existence for over five years with successful new wells and rework wells selling both gas and oil.

 

PMDP News:

 

July 15 - Plateau Mineral Development, Inc. Announces Solar Collector

 

Plateau Mineral Development, Inc. (OTC: PMDP), along with its partner, Plateau Mineral Development LLC, announced today that the firm, in conjunction with MEI, is moving to secure several features of its improved solar collector.

 

The unit, produced and installed in the early 1980s, is being upgraded with the inclusion of photo-voltaic capability. The unit acts as a concentrator under clear skies and as a flat plate when sunlight is diffused by dust or clouds.

 

A representative of Plateau Mineral Development states, "Additionally, a research and development plan and budget have been prepared to research means of enhancing the photo-voltaic output. Understandably, aspects of this research and development are being held in strictest confidence. We will update our shareholders on portions of the research that are deemed appropriate for dissemination as soon as the details are available to us."

 

LIFELINE BIOTECHNOLOGIES INCORPORATED (OTC: LLBO)

"Up 35.00% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/LLBO.php

 

Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early detection, diagnosis, and quick recovery of various disease conditions. The company is developing a non-imaging technology, known as the First Warning System, which measures tissue activity for the early detection of breast cancer in women.

 

LLBO News:

 

July 24 - Skymark Research Initiates Complimentary Research Coverage On Lifeline BioTechnologies, Inc.

 

Skymark Research, a leading provider of small- and micro-cap independent investment research, initiated coverage on Lifeline BioTechnologies, Inc. (OTC: LLBO). Skymark Research is currently offering a complimentary trial subscription. To view the company's research report on LLBO, go to www.skymarkresearch.com.

 

BIZAUCTIONS INCORPORATED (OTC: BZCN)

"Up 35.71% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/BZCN.php

 

BizAuctions, Inc. is a prime provider of commercial eBay liquidation services for excess inventory, overstock items, and returns. Our clients have included some of the Nation's leading retail names at the forefront of their industries. BizAuctions addresses the $60 billion excess inventory problem for clients by sending trucks to pick up pallets of excess inventory, selling the inventory on eBay, and collecting payment. We provide our clients with a new sales channel to generate additional revenue on excess inventory, while at the same time freeing up their valuable storage and retail space. With a long-term strategy to provide eBay liquidation services to Fortune 1000 enterprises, BizAuctions is a clear and lucrative solution for most any business to liquidate its excess inventory on eBay.

 

BZCN News:

 

July 23 - BizAuctions' Retail Store Gaining Sales in 7th Week of Operations

 

BizAuctions, Inc. (OTC: BZCN), a prime provider of commercial eBay liquidation services for excess inventories, overstocks, and returns, announced today that its recently opened retail clothing store, Lucky 7's, continues to gain sales on a weekly basis after its seventh full week of retail operations.

 

"Lucky 7's is in its seventh full week of retail operations and sales have continued to increase weekly since the opening of the store on May 29, 2009. We are building a solid base of repeat customers and are continuing to see new customers looking for great buys on our name brand clothing and merchandise," noted Delmar Janovec, BizAuctions, CEO.

 

Janovec added, "Lucky 7's customer base is building by word-of-mouth from its repeat customers as minimal amounts have been spent for advertising. If our retail operations are as successful as we plan, we should see additional revenue growth while providing our customers with name brand products at reasonable prices."

 

BizAuctions' clients have included some of the Nation's leading retail names at the forefront of their industries. With a long-term strategy to provide eBay liquidation services to Fortune 1000 enterprises, BizAuctions is a clear and lucrative solution for most any business to liquidate excess inventory on eBay.

 

DISCOVERY LABS INCORPORATED (NASDAQ: DSCO)

"Up 15.43% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/DSCO.php

 

Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 Surfactant Technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary Capillary Aerosolization Technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs is focused initially on developing its KL4 surfactant pipeline to build a pediatric franchise that will potentially address several respiratory conditions affecting neonates and young children, beginning with Respiratory Distress Syndrome (RDS).

 

DSCO News:

 

July 23 - Discovery Labs Schedules Conference Call and Webcast

 

Discovery Laboratories, Inc. (Nasdaq: DSCO) will be hosting a conference call on Wednesday, July 29, 2009 at 10:00 AM EDT. Management will provide an update on business activities as well as financial results for the second quarter of 2009.

 

Participants are encouraged to access this audio webcast through a live broadcast on the Company's website at www.discoverylabs.com. The webcast is also accessible on the Internet at http://bit.ly/FWuZv. It is recommended that participants log onto one of these sites at least 15 minutes prior to the call. The Internet broadcast will be available for up to 30 days after the call at both website addresses.

 

The call in number is 866-332-5218. The international call in number is 706-679-3237. A replay of the conference call will be available two hours after the call is completed. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 21040796.

 

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

 

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

 

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

 

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

 

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

 

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org.

 

Disclosure: OTCPicks.com has been compensated seven thousand five hundred dollars by a third party (Blue Wave Advisors) for ALRX advertising and promotional services. OTCPicks.com has been compensated three thousand five hundred dollars by a third party (Longview Communications Corp.) for ACCP advertising and promotional services. OTCPicks.com has been compensated eight thousand dollars by a third party (Mickey Reno) for NVSR advertising and promotional services. OTCPicks.com has been compensated three hundred thousand free trading shares from a third party (Cap Inc.) for LVLV advertising and promotional services. OTCPicks.com has been compensated a total of two million free trading shares by a non-controlling third party (Microcap Management) for BBYB advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.